Discovery Research From The Editor

  1. Early-Phase Formulation Done Right: An Expert Analysis 6/12/2025

    Dileep Boinipally has extensive experience in formulation, manufacturing process development, and regulatory strategy. He’s adept at explaining all that, but Chief Editor Louis Garguilo got him to focus for readers on the ins-and-outs of the practice of early formulation development.

  2. A Psychedelic Path To CDMO Selection? 6/5/2025

    "Be prepared. Structured. Work in a systematic fashion towards your CDMO selection." That's a rather non-psychedelic paraphrasing of Anthony Grenier, Reunion Neuroscience, a biotech pursuing the development of novel, synthetic psychedelic molecules. Here's more of his thoughts on CDMO selection.

  3. Evolve Or Fade Away? Biotech's Outsourcing Moment In Trump's Tariff Tangle 5/22/2025

    Ali Pashazadeh is "a deep thinker" that our Chief Editor visits with annually. Recently, he asked Pashazadeh to help us think through the evolving policies of the new U.S. presidential administration and the tariff turbulence, as they relate to a biotech's development and manufacturing outsourcing.

  4. Lilly's CEO Building On The Trump Agenda 5/12/2025

    “We hadn’t built a new site in the U.S. in more than 40 years until the first set of Trump tax cuts, so we need to see those either extended or improved to support this,” Eli Lilly CEO David Ricks recently said, announcing — in Washington, DC — plans to invest $27 billion to build four new manufacturing plants in the U.S.

  5. Investors Create A U.S. Biotech With GLP-1 Assets From China 5/7/2025

    U.S.-based Kailera Therapeutics formation is a revelatory story highlighting the prowess of today’s investor class. All four of its clinical candidates are GLP-1-based therapies. All were in-licensed from China. Kailera's CTO Doug Bakan fills us in on how it came together, and what's next.

  6. Tariffs Won't Stop Drug-Candidate Licensing From China Biotechs 4/23/2025

    According to Global Data, the total deal value of U.S. licensing of innovator drug candidates from Chinese biopharma companies has surged since 2020. This is an area way upstream of the current tariff focus on manufacturing. But how this R&D trend and those tariffs play out will impact your U.S.-based CDMOs.

  7. What If The Trump Tariff Strategy Works? 4/8/2025

    Doom and gloom in the drug development and manufacturing supply chain.  Predictions of disruptions and displacements. The Trump tariff ploy will fail, and costs/prices will skyrocket. But have you considered this “risk”? The tariff tantrum lowers national export/import duties for the entire globe.

  8. Pain And Pleasure In Project Management Of CDMOs 3/17/2025

    Tony Sampognaro of Stoke Therapeutics, says, “We're having to rearrange and bolster the constellation of CDMOs we're working with." The nice thing is, Stoke has a comprehensive extended enterprise model. Nonetheless, an all-outsourced model “can add hidden complexity." Here's how to manage that.

  9. 'Fractional Hiring' At Your CDMO. Okay With You? 3/14/2025

    We need a flexible hiring marketplace – a new ecosystem – to generate increased awareness by professionals and students of positions in the biopharma industry. “It’s no longer about simply posting full-time jobs,” says Chris Frew, Founder/CEO of BioBuzz Networks. But is "fractional hiring" the answer?

  10. Smart Scale-Up: Expanding Viral Vectors With Microcarrier Bead Technology 3/12/2025

    Scale up your manufacturing of adherent cell cultures used for viral vector-based treatments with the novel technologies needed to facilitate safe, rapid production.